Growth In The Onpattro Market Is Being Driven By Rising Autoimmune Disorders Fueling The Growth Of The Due To Increasing Demand For Symptom Management And Complication Prevention

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Projected Increase In Market Value Of The Onpattro Market During 2026–2030?

Historical growth was fueled by progress in RNA-based drug development, a rise in the diagnosis of hATTR amyloidosis, the granting of regulatory approvals for gene-silencing therapies, the expansion of specialty infusion centers, and the clinical confirmation of patisiran’s effectiveness.

Over the forecast period, growth is expected due to the expansion of next-generation RNA therapeutics, increased investment in rare disease pipelines, a heightened focus on personalized medicine, the creation of subcutaneous delivery alternatives, and the rising uptake of genetic screening programs.

Significant trends anticipated for the forecast period include the increasing adoption of RNA interference therapies, a greater emphasis on treating rare genetic diseases, the broadening of precision gene silencing approaches, enhanced clinical outcomes in amyloidosis care, and the growing integration of advanced infusion therapies.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20169&type=smp

What Key Drivers Are Fueling The Growth Of The Onpattro Market?

The increasing incidence of hereditary transthyretin-mediated amyloidosis is anticipated to drive the expansion of the onpattro market in the future. This condition, also known as hATTR, is an uncommon genetic illness characterized by the formation of detrimental deposits from mutated TTR proteins, impacting both the nervous system and cardiac function. The growing occurrence of hATTR is fueled by improved diagnostic methods, widespread genetic screening, and enhanced public understanding, leading to the identification of more patients. Onpattro serves as a treatment for hereditary transthyretin-mediated amyloidosis by inhibiting the transthyretin (TTR) gene, thereby decreasing amyloid protein synthesis and mitigating organ harm. For example, data from February 2024, sourced from Verywell Health, a U.S. health information platform, indicates that hereditary transthyretin-mediated amyloidosis impacts 5,500–38,500 individuals worldwide. In the U.S., estimates for hereditary transthyretin-mediated amyloidosis with polyneuropathy range from 104 to 3,847 cases, underscoring substantial underdiagnosis. Consequently, the increasing prevalence of hereditary transthyretin-mediated amyloidosis is a key factor propelling the expansion of the onpattro market.

What Are The Key Segment Divisions In The Onpattro Market Segment Structure?

The onpattro market covered in this report is segmented –

1) By Clinical Indication: Hereditary Transthyretin-Mediated Amyloidosis, Wild-Type Transthyretin Amyloidosis, Other Transthyretin-Related Amyloidoses

2) By Distribution Channel: Direct Sales, Pharmacies, Online Pharmacies

3) By End User: Hospitals, Specialty Clinics, Home Healthcare Providers

What Trends Are Influencing The Onpattro Market?

A prominent trend within the onpattro market involves broadening the drug’s approved uses via supplemental drug applications, thereby seeking to enhance its market reach and address a greater diversity of patient requirements. These applications typically serve to enlarge a drug’s sanctioned applications, for instance, by targeting novel indications, patient groups, or formulations, which expands its therapeutic scope and potential in the market. An example of this is seen in February 2023, when Alnylam Pharmaceuticals, a US-based firm, declared the acceptance of an sNDA for ONPATTRO (patisiran), seeking approval for the treatment of cardiomyopathy linked to transthyretin amyloidosis (ATTR). ONPATTRO itself is an RNA interference (RNAi) therapeutic engineered to specifically target the transthyretin (TTR) protein, which can accumulate abnormally in ATTR amyloidosis patients, causing serious complications like cardiomyopathy. Initially, the drug received approval in 2018 for addressing polyneuropathy associated with hereditary ATTR amyloidosis. The foundation for this recent sNDA submission stemmed from outcomes of the Phase III APOLLO-B study, which indicated a notable improvement in both functional capacity and quality of life for cardiomyopathy patients treated with patisiran, versus a placebo.

Which Organizations Are Engaged In The Onpattro Market?

Major companies operating in the onpattro market are Alnylam Pharmaceuticals Inc.

Get The Full Onpattro Market Report:

https://www.thebusinessresearchcompany.com/report/onpattro-global-market-report

Which Region Is The Leading Market For The Onpattro Market?

North America was the largest region in the onpattro market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the onpattro market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Onpattro Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/onpattro-global-market-report

Browse Through More Reports Similar to the Global Onpattro Market 2026, By The Business Research Company

Online Insurance Market Report 2026

https://www.thebusinessresearchcompany.com/report/online-insurance-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

On Demand Transportation Market Report 2026

https://www.thebusinessresearchcompany.com/report/on-demand-transportation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795